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Summary
Background Smoking cessation programmes delivered via mobile phone text messaging show increases in self-
reported quitting in the short term. We assessed the eﬀ ect of an automated smoking cessation programme delivered 
via mobile phone text messaging on continuous abstinence, which was biochemically veriﬁ ed at 6 months.
Methods In this single-blind, randomised trial, undertaken in the UK, smokers willing to make a quit attempt were 
randomly allocated, using an independent telephone randomisation system, to a mobile phone text messaging 
smoking cessation programme (txt2stop), comprising motivational messages and behavioural-change support, or to 
a control group that received text messages unrelated to quitting. The system automatically generated intervention or 
control group texts according to the allocation. Outcome assessors were masked to treatment allocation. The primary 
outcome was self-reported continuous smoking abstinence, biochemically veriﬁ ed at 6 months. All analyses were by 
intention to treat. This study is registered, number ISRCTN 80978588.
Findings We assessed 11 914 participants for eligibility. 5800 participants were randomised, of whom 2915 smokers 
were allocated to the txt2stop intervention and 2885 were allocated to the control group; eight were excluded because 
they were randomised more than once. Primary outcome data were available for 5524 (95%) participants. Biochemically 
veriﬁ ed continuous abstinence at 6 months was signiﬁ cantly increased in the txt2stop group (10·7% txt2stop 
vs 4·9% control, relative risk [RR] 2·20, 95% CI 1·80–2·68; p<0·0001). Similar results were obtained when participants 
that were lost to follow-up were treated as smokers (268 [9%] of 2911 txt2stop vs 124 [4%] of 2881 control [RR 2·14, 
95% CI 1·74–2·63; p<0·0001]), and when they were excluded (268 [10%] of 2735 txt2stop vs 124 [4%] of 2789 control 
[2·20, 1·79–2·71; p<0·0001]). No signiﬁ cant heterogeneity was shown in any of the prespeciﬁ ed subgroups.
Interpretation The txt2stop smoking cessation programme signiﬁ cantly improved smoking cessation rates at 6 months 
and should be considered for inclusion in smoking cessation services. 
Funding UK Medical Research Council, Primary Care Research Networks.
Introduction
Tobacco use is a leading cause of preventable death, and 
is estimated to cause more than 5 million deaths a year 
worldwide.1,2 In the UK, two-thirds of smokers report that 
they would like to stop.3 Eﬀ ective interventions to support 
smoking cessation are urgently needed.
Mobile phone technology has the potential to provide 
personalised smoking cessation support. Motivational 
messages and behaviour-change methods used in face-to-
face smoking cessation support can be modiﬁ ed for delivery 
via mobile phones with the content tailored to the age, sex, 
and ethnic group of the quitter.4,5 In this way, support can 
be delivered wherever the person is located, without them 
having to attend services, and can be interactive, allowing 
quitters to obtain extra help when needed.4,5
Because of the widespread ownership of mobile 
phones, fully automated smoking cessation support can 
be delivered to large numbers of people at low cost. 
In 2009, more than two-thirds of the world’s population 
owned a mobile phone and 4·2 trillion text messages 
were sent.6 In the UK, there are about 120 mobile phone 
subscriptions per 100 population, with ownership greater 
than 80% in all socioeconomic groups.7
Although smoking cessation support delivered through 
mobile phone text messaging has been shown to increase 
self-reported smoking abstinence at 6 weeks,8,9 the extent 
to which these early beneﬁ ts are maintained at 6 months 
and can be validated biochemically needs further 
investigation. In this study, we assessed the eﬀ ects of the 
txt2stop mobile phone text messaging smoking cessation 
programme on biochemically veriﬁ ed continuous 
smoking abstinence at 6 months.
Methods
Study design and participants
txt2stop is a single-blind, randomised, trial of personalised 
smoking cessation advice and support by mobile phone 
text messages. The trial was undertaken in the UK and 
participants were randomised between Oct 15, 2007, and 
June 1, 2009; the protocol was published in 2008.10 
Smokers aged 16 years or older, willing to make an 
attempt to quit smoking in the next month, were eligible 
for inclusion if they owned a mobile phone and gave 
informed consent.
We advertised the trial to smokers on the radio, bus 
billboards, and websites, and in newspapers, primary 
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care centres, pharmacies, and smoking cessation services. 
Potential participants registered their interest by text 
message or online. Research assistants then telephoned 
respondents to assess eligibility and collect baseline data. 
Trial information was posted or emailed and was available 
online. Participants provided consent by sending a text 
message to the trial coordinating centre. Medical research 
ethics committee approval was obtained from the 
St Thomas’ Hospital Research Ethics Committee (COREC 
ref 06/q0702/169T).
Randomisation and masking
We randomised participants using an independent 
telephone randomisation system that included a 
minimisation algorithm balancing for sex (male, 
female), age (16–18 years, 19–34 years, and >34 years), 
educational level (to age ≤16 years, >16 years), and 
Fagerstrom score for nicotine addiction (≤5, >5). The 
system automatically generated intervention or control 
group texts according to the allocation. Researchers 
who gathered data and under took laboratory analyses 
were masked to treatment allocation.
Procedures
All participants were free to participate in any other 
smoking cessation service or support that they wished to 
use, and were oﬀ ered the QUIT and National Health 
Service (NHS) smoking cessation helpline numbers. 
Participants in the intervention group were asked to set a 
quit date within 2 weeks of randomisation. They received 
ﬁ ve text messages a day for the ﬁ rst 5 weeks and then 
three a week for the next 26 weeks. Messages were 
developed with the input of smokers and smoking 
cessation professionals. The intervention included 
motivational messages and behaviour-change techniques 
(panel 1). Messages encouraged participants to persevere 
with the quit attempt and focused on their success so far. 
They provided positive feedback and emphasised the 
beneﬁ ts achieved by quitting and provided information 
about the consequences of smoking, how to quit and stay 
quit, and how others would approve of quit success. They 
prompted participants to get rid of cigarettes, ashtrays, 
and lighters, and to avoid environments where they 
would normally smoke, and encouraged participants to 
identify the challenges of quitting and plan how to 
overcome them. The messages also promoted the use of 
the QUIT smoking cessation telephone helpline and 
nicotine replacement therapy.
The programme was also personalised with an 
algorithm based on demographic and other information 
gathered at baseline, such as smokers concerns about 
weight gain after quitting. By texting the word “crave”, 
participants with cigarette cravings would receive 
instant messages to distract and support them during 
their episode of craving. They could also request the 
mobile phone number of another trial participant so 
that they could text each other for support. By texting 
the word “lapse”, participants would receive a series of 
three text messages that encouraged them to continue 
with their quit attempt. Participants in the intervention 
group using pay-as-you-go mobile phone schemes were 
given a £20 top-up voucher to provide suﬃ  cient credit 
to participate in the intervention. Participants were not 
able to reset the intervention programme if their quit 
attempt failed. The core programme consisted of 
Panel 1: Examples of intervention-group text messages
In lead-up to quit date
“To make things easier for yourself, try having some 
distractions ready for cravings and think up some personal 
strategies to help in stressful situations”; “why not write an 
action list of your reasons why you want to quit. Use it as 
your inspiration.”
Message relating to speciﬁ c issues
“TXT2STOP: Think you’ll put on weight when you quit? We’re 
here to help - We’ll TXT weight control and exercise tips, 
recipes, and motivation tips.”
On quit date
“This is it! - QUIT DAY, throw away all your fags. TODAY is the 
start of being QUIT forever, you can do it!”
After quit day
“TXT2STOP: Quick result! Carbon monoxide has now left your 
body!”; “Day4=Big day - cravings still strong? Don’t worry 
tomorrow will be easier! Keep your mind & hands busy. Save 
this txt so u can txt CRAVE to us at any time during the 
programme.”
In response to text “crave” request
“Cravings last less than 5 minutes on average. To help distract 
yourself, try sipping a drink slowly until the craving is over.”
In response to text “lapse” request
“Don’t feel bad or guilty if you’ve slipped. You’ve achieved a 
lot by stopping for a while. Slip-ups can be a normal part of 
the quitting process. Keep going, you can do it!”
Panel 2: Examples of control-group text messages
• “Thanks for taking part! Without your input, the study 
could not have gone ahead!”
• “Thanks for taking part. Remember, if you have changed 
contact details please let us know. We will need to contact 
you at the end of the study.”
• “Being part of this will help others in the future. Thanks 
for your help!”
• “Thanks for taking part! The study is important and is 
supported by the UK Medical Research Council.”
• “Only 4 more weeks to go until completion of the study!”
• “We will be contacting you soon to collect ﬁ nal 
information. Any change in contact details txt us 
on 65151. Thanks once again!”
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186 messages and the personalised messages were 
selected from a database of 713 messages. A detailed 
description of the modiﬁ cation and development of the 
txt2stop intervention from the STOMP (stop smoking 
with mobile phones) intervention will be reported 
elsewhere.4,5 Control group participants received fort-
nightly, simple, short, text messages related to the 
importance of trial participation (panel 2). We used 
evidence-based methods to maximise response rates.11
The primary outcome was self-reported continuous 
smoking abstinence, biochemically veriﬁ ed at 6 months. 
Self-reported continuous abstinence was deﬁ ned as no 
more than ﬁ ve cigarettes smoked in the past week at 
4 weeks follow-up and no more than ﬁ ve cigarettes smoked 
since the start of the abstinence period at 6 months of 
follow-up.12 Secondary outcomes were point prevalence of 
abstinence (ie, no smoking in the past 7 days) at 4 weeks 
and 6 months, and self-reported continuous abstinence 
since the start of the abstinence period, 28-day abstinence, 
involvement in any vehicle crashes,13 repetitive strain 
injury (thumb) at 6 months, and use of other smoking 
cessation services during the trial.
Postal salivary-cotinine testing was used to verify self-
reported continuous abstinence at 6 months, with a cut-
oﬀ  of 7 ng/mL cotinine. This metabolite of nicotine has 
an in-vivo half-life of about 20 h and can be used to 
distinguish smokers from non-smokers with a cutoﬀ  of 
7 ng/mL, with 92% sensitivity and 90% speciﬁ city. Postal 
testing is practicable and reliable with respect to chemical 
stability of salivary cotinine samples.14–16 Research 
assistants oﬀ ered those who did not provide a saliva 
sample a carbon monoxide test in-person, with a cutoﬀ  
of 6 ppm, which has 97% sensitivity and 70% speciﬁ city.17 
Participants reporting abstinence whose test showed 
that they were smokers were counted as smokers in the 
analysis. Participants who reported continuous abstin-
ence but who subsequently reported that they were 
smoking again were classed as smokers in the analysis. 
Participants directly entered data on a website, or 
research assistants directly entered data given to them 
by telephone. Paper and email data were double entered 
into the database by study staﬀ .
We planned to report the eﬀ ects of the inter vention 
subdivided by the following prespeciﬁ ed sub groups: age 
(<35 years, ≥35 years), nicotine addiction (Fagerstrom 
score >5, ≤5), employment status (non-manual, manual, 
unemployed, or student), receipt of a mobile phone top-
up voucher (yes, no), and use of other smoking cessation 
treatments or services (yes, no).
Statistical analysis
The statistical analysis plan was approved by the Trial 
Steering Committee before unblinding. On the basis of 
the results of a pilot study we estimated that the control 
group quit rate would be around 7%. On the basis that 
even a 2·5% absolute diﬀ erence in abstinence would be 
important (ie, 9·5% vs 7%; relative risk [RR] 1·36), we 
calculated that study size of 5800 participants, allowing 
for a 10% loss to follow-up, would have a 90% chance of 
detecting a signiﬁ cant diﬀ erence. Tests were two-sided, 
with p values of less than 0·05 judged as signiﬁ cant. All 
analyses were undertaken on an intention-to-treat basis 
with STATA (version 11.2). Eﬀ ect measures were RRs and 
95% CIs with 99% CIs for subgroup analyses to minimise 
the chances of identifying false-positive eﬀ ects. We 
assessed homogeneity in treatment eﬀ ects within 
subgroups with a χ² test. For the primary analysis we 
used multiple imputation, which uses the observed 
predictors of outcome and the predictors of loss to follow-
up to impute missing outcome data, thus attempting to 
correct for any potential bias caused by missing data.18,19
We constructed four univariate imputation models for 
the incomplete variables: ethnic group, 4-week point-
prevalence outcome, 22-week continuous abstinence, 
and biochemically veriﬁ ed smoking cessation at 22 weeks. 
The covariates that were included in all four models 
were: sex; age (years); educational level (to age ≤16 years, 
>16 years); nicotine dependence (Fagerstrom score 1–10); 
number of previous attempts to quit; ethnic group; 
employment; and completeness of contact details for 
home address, home postcode, home telephone number, 
email, work address or telephone number, and alternative 
contact address or telephone number. The model to 
Figure 1: Trial proﬁ le
11 914 assessed for eligibility
5800 randomised
8 excluded because randomisation occurred
more than once
6114 excluded
1287 did not meet inclusion criteria
4406 did not consent
421 consented but not randomised
2911 allocated to intervention
2509 received entire intervention
402 discontinued intervention
121 lost to follow-up
16 withdrew from the trial
105 did not complete self-reported smoking status
444 selected for biochemical assessment of smoking
(self-reported continuous abstinence)
364 completed biochemical assessment
55 no follow-up
25 self-reported smoking again
2735 followed up
222 selected for biochemical assessment of smoking
(self-reported continuous abstinence)
178 completed biochemical assessment
19 no follow-up
25 self-reported smoking again
2789 followed up
2911 analysed
0 excluded from analysis
2881 allocated to control
2734 received entire control
147 discontinued control
73 lost to follow-up
20 withdrew from the trial
53 did not complete self-reported smoking status
2881 analysed
0 excluded from analysis
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impute 4-week point prevalence also included imputed 
ethnic group.
The model to impute 22-week continuous abstinence 
included imputed ethnic group and imputed 4-week 
abstinence. The model to impute biochemically veriﬁ ed 
smoking cessation at 22 weeks included imputed ethnic 
group, 4-week abstinence, and 22-week continuous 
abstinence. 100 imputed datasets were generated. We 
combined point estimates and standard errors with 
Rubin’s rules.18 The same procedures were used for all 
secondary outcomes. We did two secondary analyses: 
ﬁ rst, we assumed that all participants with missing 
outcome data were smokers;20 and second, we did a 
complete case analysis in which any participants with 
missing information on any outcome were excluded.19
This study is registered, number ISRCTN 80978588.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. CF had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
5800 participants were randomly assigned to the txt2stop 
intervention or control group (ﬁ gure 1). Eight participants 
(four in each group) were excluded from the trial because 
they were randomised more than once. Treatment groups 
were well balanced with respect to baseline character istics 
(table 1). Primary outcome data were available for 
2735 (94%) participants in the intervention group and 
2789 (97%) in the control group (ﬁ gure 1). 592 (89%) parti-
ci pants self-reporting continuous abstinence at 6 months 
completed follow-up. 542 provided samples for veriﬁ cation 
and 50 subsequently reported that they had started 
smoking again. Two participants refused cotinine testing 
but accepted carbon monoxide testing. In 150 (28%) of 
542 participants who self-reported abstin ence, the salivary 
cotinine results showed that they were smoking.
Biochemically veriﬁ ed continuous abstinence at 
6 months was signiﬁ cantly increased with the txt2stop 
intervention (table 2). Similar results were obtained when 
the participants who were lost to follow-up were treated 
as smokers (268 [9%] of 2911 txt2stop vs 124 [4%] of 2881 
control; RR 2·14, 95% CI 1·74–2·63; p<0·0001), and 
when they were excluded (268 [10%] of 2735 txt2stop vs 
124 [4%] of 2789 control; RR 2·20, 95% CI 1·79–2·71; 
p<0·0001). When the data from the txt2stop trial were 
combined with those from the txt2stop pilot phase, the 
pooled RR for biochemically veriﬁ ed continuous 
abstinence at 6 months was 2·16 (95% CI 1·77–2·62).
Table 2 shows self-reported smoking cessation 
outcomes at 4 weeks and 6 months. We identiﬁ ed no 
evidence of any adverse eﬀ ects of the txt2stop 
intervention on thumb pain while texting or on road 
traﬃ  c accidents (table 2), and no evidence of hetero-
Intervention 
(SE) 
Control 
(SE) 
Relative risk 
(95% CI)
p value
Primary outcome
Biochemically veriﬁ ed continuous 
abstinence at 6 months
10·7% (0·6) 4·9% (0·4) 2·20 (1·80–2·68) <0·0001
Secondary outcomes (4 weeks)
Self-reported no smoking in past 7 days 28·7% (0·8) 12·1% (0·6) 2·37 (2·11–2·66) <0·0001
Secondary outcomes (6 months)
Self-reported 28-day continuous abstinence 19·8% (0·8) 13·5% (0·7) 1·47 (1·30–1·66) <0·0001
Self-reported no smoking in past 7 days 24·2% (0·8) 18·3% (0·8) 1·32 (1·19–1·47) <0·0001
Self-reported involvement in vehicle crashes 4·5%(0·4) 3·8% (0·4) 1·16 (0·89–1·51) 0·269
Pain in thumb while texting 4·5% (0·4) 4·5% (0·4) 1·00 (0·78–1·28) 0·985
Data are percentage (SE) or relative risk (95% CI). Multiple imputation by chained equations (number of 
imputations=100).
Table 2: Primary and secondary outcomes
Intervention group
(n=2911)
Control group
(n=2881)
Sex 
Male 1608 (55%) 1585 (55%)
Female 1303 (45%) 1296 (45%)
Age (years) 36·8 (11·0) 36·9 (11·1)
Age (years)
16–18 95 (3%) 100 (3%)
19–34 1198 (41%) 1199 (42%)
>34 1618 (56%) 1582 (55%)
Ethnic origin
White 2589 (89%) 2541 (88%)
Black 119 (4%) 121 (4%)
Asian 117 (4%) 125 (4%)
Chinese 3 (<1%) 6 (<1%)
Other 64 (2%) 70 (2%)
Refused 19 (1%) 18 (1%)
Full-time education 
Yes 200 (7%) 178 (6%)
No 2711 (93%) 2703 (94%)
Age education stopped (years)
≤16 1274 (44%) 1260 (44%)
>16 1637 (56%) 1621 (56%)
Employment type
Manual 913 (31%) 874 (30%)
Non-manual 1264 (43%) 1275 (44%)
Student or unemployed 734 (25%) 732 (25%)
Previous quit attempts
Never 117 (4%) 140 (5%)
1–5 times 2150 (74%) 2178 (76%)
≥6 times 644 (22%) 563 (20%)
Fagerstrom score
≤5 1747 (60%) 1734 (60%)
>5 1164 (40%) 1147 (40%)
Data are n (%) or mean (SD).
Table 1: Baseline data of participants
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geneity for any of the prespeciﬁ ed subgroup analyses 
(ﬁ gure 2). During the trial other smoking cessation 
support or services were used by 1302 (50%) of 2604 of 
the txt2stop group versus 1269 (49%) of 2587 of the 
control group (RR 1·02, 95% CI 0·96–1·08).
Discussion
Smoking cessation support delivered via mobile phone 
text messaging doubles quit rates at 6 months (panel 3). 
The intervention is eﬀ ective in all socioeconomic groups 
and in younger and older smokers. This study has 
several strengths. The use of telephone randomisation 
ensured that study staﬀ  had no foreknowledge of 
treatment allocation. Baseline prognostic factors were 
well balanced between groups. Researchers who 
gathered data and undertook laboratory analyses were 
masked to treatment allocation, and the primary 
outcome, biochemically veriﬁ ed continuous abstinence, 
was known for 92% of trial participants. All analyses 
were on an intention-to-treat basis.
Although response rates for biochemically veriﬁ ed 
abstinence at 6 months were high, some potential for bias 
existed. Our primary analysis used multiple imputation 
methods because evidence shows that the assumptions 
underpinning this method are more defensible than are 
those assumed when using other approaches to missing 
data.19,20 Nevertheless, we also did sensitivity analyses with 
the traditional approaches to missing data in smoking 
cessation studies. The results of sensitivity analyses also 
showed a signiﬁ cant doubling of quit rates.
Our trial has some limitations. Although eﬀ orts were 
made to ensure that the research staﬀ  remained masked 
to whether a participant was in the intervention or control 
group, occasionally trial participants would reveal this 
information to the study staﬀ . Although this information 
could have biased our estimates of self-reported 
abstinence, our primary endpoint, biochemically veriﬁ ed 
self-reported smoking abstinence, should be unbiased. 
In trials of behaviour change, in which participants 
cannot be adequately masked to allocation of intervention, 
participants who have been allocated to the control group 
could have reduced motivation to quit. To minimise this 
eﬀ ect we oﬀ ered all participants contact details for 
existing NHS smoking cessation services.
Self-reported continuous abstinence with biochemical 
veriﬁ cation with cotinine or carbon monoxide tests is the 
recommended standard for assessment of smoking 
cessation in trials (the Russell standard).12 However, the 
biochemical tests are not perfect. Cotinine has an in-vivo 
half-life of about 20 h, and can only be detected with a 
cotinine test for a few days after the use of tobacco. 
Carbon monoxide can be detected only for about 24 h 
after tobacco use. In any trial of a smoking cessation 
intervention, some participants could be embarrassed 
that they had not managed to stop smoking and might 
state they had stopped smoking. Such smokers then 
might stop smoking before providing a sample for 
testing. However, if a smoker wanted their cotinine test 
to record them as a non-smoker, they would ﬁ rst need to 
know how long to quit for in order for their saliva to test 
Figure 2: Eﬀ ect of the txt2stop intervention on the primary outcome by subgroup (multiple imputation by 
chained equations)
*99% CI for relative risks of subgroups. †95% CI for overall relative risk.
Age (years)
<35
≥35
Employment type
Manual
Non-manual
Student or unemployed
Fagerstrom score
≤5
>5
Use of a smoking cessation product or
service at the time of randomisation
Yes
No
On Pay-As-You-Go-scheme
Yes
No
Overall
Two-sided intervention eﬀect p value<0·0001
Overall interaction p value=0·388
0·8
Control better
Intervention
(SE)
Control
(SE)
Subgroup
relative risk (99% CI)*
Intervention better
1·0 2·0 3·0 4·0 5·0
 10·4% (0·9)
 10·9% (0·8)
 9·8% (1·0)
 11·9% (0·9)
 9·8% (1·2)
 12·1% (0·8)
 8·6% (0·9)
4·1% (0·6)
5·5% (0·6)
4·1% (0·7)
5·1% (0·6)
5·5% (0·9)
5·3% (0·6)
4·3% (0·6)
2·55 (1·68–3·89)
1·98 (1·42–2·76)
2·42 (1·44–4·07)
2·34 (1·60–3·42)
1·79 (1·08–2·96)
2·29 (1·66–3·15)
2·03 (1·29–3·20)
 14·6% (1·9)
 10·1% (0·6)
 10·8% (1·0)
 10·6% (0·8)
 10·7% (0·6)
9·6% (1·5)
4·1% (0·4)
4·9% (0·7)
4·9% (0·5)
4·9% (0·4)
1·51 (0·90–2·55)
2·45 (1·81–3·32)
2·21 (1·45–3·36)
2·19 (1·57–3·06)
2·20 (1·80–2·68)†
Panel 3: Research in context
Systematic review
We did a systematic review of mobile-technology-based interventions for health and 
health services.20 We identiﬁ ed 131 trials, of which ﬁ ve were trials of smoking cessation 
support delivered via mobile text messaging. Two reported doubling of self-reported 
smoking cessation at 4 weeks (pooled relative risk [RR] 2·18, 95% CI 1·80–2·65), but 
limitations in the trials aﬀ ected the validity of results at 6 months.4,5 In one trial 
diﬀ erential losses to follow-up occurred and few participants were selected for 
biochemical validation of results at 6 months.5 Another trial was too small to provide a 
precise estimate of eﬀ ect at 6 months (RR 1·28, 95% CI 0·46–3·56).4 One other trial of text 
message support reported eﬀ ects on the number of cigarettes smoked per day at 
3 months (mean diﬀ erence 0·70, 95% CI –2·03 to 2·43).21 Two trials of interventions using 
internet, email, and mobile technologies equally, reported doubling in self-reported 
abstinence at 12 months (RR 2·03, 95% CI 1·40–2·94).22,23
Interpretation
The self-reported smoking cessation results at 4 weeks and 6 months in this trial are 
similar to those reported in previous trials of smoking cessation support delivered via 
mobile phone text messaging. However, biochemical testing showed that more than a 
quarter of participants self-reporting quitting were smokers. This trial is the ﬁ rst to report 
the eﬀ ect of text messaging smoking cessation support on biochemically veriﬁ ed 
abstinence at 6 months. On the basis of these results the txt2stop intervention should be 
considered as an addition to existing smoking cessation services.
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negative. They would then have to successfully quit for a 
few days before providing the cotinine sample.
Although the speciﬁ city and sensitivity of the cotinine 
and carbon monoxide tests that we used to conﬁ rm 
smoking status are high, they are not 100%, so some 
misclassiﬁ cation is inevitable.14,17,24 However, mis classi-
ﬁ cation is likely to have biased our estimate of the relative 
risk towards the null. The £20 top-up voucher given to 
participants using pay-as-you-go schemes for their mobile 
phone (also known as prepaid in some countries) might 
have been an incentive for some non-smokers to state they 
were smokers and to join the trial only to obtain these 
vouchers. However, once again any misclassiﬁ cation 
should be non-diﬀ erential and would not explain our 
signiﬁ cant results.
We randomly assigned four people twice and excluded 
them from the analysis. We could have randomised other 
participants more than once, but only if they had obtained 
a new mobile phone number and used false names and 
dates of birth. If this occurred, this could reduce the 
power of the trial to detect an eﬀ ect of the txt2stop 
intervention on continuous abstinence.
A limitation of the trial is that it provides little insight 
into the mechanism by which txt2stop increases smoking 
cessation. No evidence of any diﬀ erence in the use of 
other smoking cessation support or services between the 
intervention and control group was shown. Our ﬁ ndings 
are not consistent with the hypothesis that the txt2stop 
intervention works by increasing the use of other eﬀ ective 
smoking cessation services. We assessed the eﬀ ect of the 
txt2stop intervention on speciﬁ c smoking cessation 
attitudes and behaviours and did qualitative interviews 
with participants about their experience of the 
intervention. We also coded the text message content of 
the intervention with a typology of behaviour-change 
techniques.25 Findings of these analyses will be reported 
separately; they provide limited data about the mechanism 
of action. As such, txt2stop should be regarded as a 
complex intervention of smoking cessation support.
The eﬀ ect of smoking cessation support delivered via 
mobile phone text messaging in this trial seems similar 
to other behavioural support interventions. The eﬀ ects 
for group counselling are pooled RR 1·98 (95% CI 
1·60–2·46), for one-to-one counselling 1·39 (1·24–1·57), 
and for telephone advice 1·29 (1·20–1·38).26–28 The control 
group quit rate and the absolute diﬀ erence in quitting 
between the intervention and control group in this trial 
is, however, lower than in many trials of group or one-to-
one counselling.
On the basis of these results the txt2stop intervention 
should be considered as an addition to existing smoking 
cessation services. In this trial the intervention was 
eﬀ ective on its own and when used alongside other 
smoking cessation interventions. To scale up the txt2stop 
intervention for delivery at a national or international 
level would be technically easy. The intervention might 
require some adaptation, translation into other languages, 
and local evaluation before delivery to other populations. 
The intervention is low cost and likely to be highly cost-
eﬀ ective. A cost-eﬀ ectiveness analysis of txt2stop will be 
reported separately.
Our ﬁ nding that the txt2stop intervention increased 
biochemically veriﬁ ed smoking cessation at 6 months 
raises the possibility that mobile-technology-based 
interventions might be eﬀ ective in changing other 
behavioural risk factors for diseases.
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